Backup Header Below

Scailyte Hosts Webinar About Supervised Learning of Disease-Associated Cell States and Dynamics

Webinar on the latest developments in the analysis of single-cell data, including from transcriptomic and imaging technologies.

 On the 15th of March, Scailyte will host a webinar with Prof. Dr Manfred Claassen, a co-founder of the company, who leads the Clinical Bioinformatics & Machine Learning in Translational Single-cell Biology group at University Hospital in Tübingen, Germany. During the webinar, Prof. Dr M. Claassen will present his research and development of supervised machine learning techniques to study disease-associated cell states and dynamics in different types of single-cell data. The speaker will also highlight the power of multimodal single-cell data integration, such as imaging flow cytometry, in situ proteomic imaging and RNA-seq data, to achieve unprecedented high precision in his studies of rare cell types and their pathologic behaviour.


Recent advances in single-cell technologies have opened the way for high-dimensional, high-throughput, and high-resolution measurements of biological systems. These methods enable the capture of rare cell populations, which play a pivotal role in the initiation and progression of diseases such as cancer. However, the identification of such subpopulations and their studies in single-cell datasets remains challenging for data scientists.


The format is the following:


5 mins – introduction

20 mins – main discussion

20 min+ – Q&A

Book your tickets here – 


About Scailyte


Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically relevant biomarker signatures by uncovering human hidden “single-cell” secrets. 


Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well-established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

Source :

Other Press Releases